…do not deserve to be called disease modifying
As promised, I am replying in a new thread as David himself stated that further off-topic discussion concerning the points he introduced shouldn’t continue on there.
It’s only the last part of these replies that we haven’t heard many times before, so I’m going to address that rather than go over old ground.
The term disease modifying drug/treatment is a term used within the MS community (including neurologists and MS nurses) to refer to beta interferon, Copaxone, Tysabri and other meds used to change the course of MS. Any other interpretation by someone familiar with the everyday use of this term is disingenuous (i.e. “not candid or sincere, typically by pretending that one knows less about something than one really does” OED on-line) so I am not about to get into that one!
DMDs are prescribed for people who have relapses. For simplicity, let’s assume that this means people with RRMS. The course of someone with RRMS varies between individuals, but the overall pattern is a series of relapses alternating with a series of remissions. Over time, residual symptoms from the relapses builds and the patient becomes more disabled. Unfortunately, the level of disability sometimes means an early death.
So, the normal course of someone with RRMS is relapses and remissions with accumulating disability and, sometimes, death.
So, anything that reduces relapses, disability or death is disease modifying.
From here, the term DMDs refers to the injectables (beta interferon and Copaxone).
David, you continually post links to the MSS info on DMDs. You have been continually advised that this information is neither up to date nor complete. You have been continually advised that if you want to understand the latest understanding of how DMDs alter the course of MS, you should look further afield at websites like pubmed and the multiple sclerosis research blogspot where leading edge science can be read. Since you appear to have no intention of updating your knowledge, here is a starter for ten. If you would like to provide more up to date information that counters it, feel free, but the same old links to out of date reports, blogs, TV programmes, newspaper comments, etc really don’t meet the grade.
DMDs reduce the number of relapses that people with RRMS have. Recent evidence suggests that Rebif44 does this significantly more than 30% of the time (see the Campath vs Rebif trial).
A very new study shows that of people who were on the original betaferon trial, those on the drug were significantly less likely to die from their MS than those who received the placebo. (And the people who received the drug only received it for 3 years.)
DMDs delay the onset of disability.
DMDs reduce cognitive decline.
DMDs reduce the severity of relapses that still occur.
DMDs prevent the development of MS. In fact, DMDs are now widely given to people with CIS. Rebif was approved for this just recently in Europe.
If you do not want to reply to this post David, then perhaps you would rather reply to the other thread (that you started)? There are many points that you promised to reply to on there by Friday 10th February. We are still waiting.